Belite Bio (STU:D01) Total Operating Expense: €87.12 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:D01 Belite Bio Inc STU:D01
20 GF Score
Price €131.00
! 3 Warning Signs
View Full Analysis

What is Belite Bio Total Operating Expense?

Belite Bio STU:D01 +1.55% 20 Total Operating Expense is €87.12 Mil as of Mar. 2026. GuruFocus rates STU:D01 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Belite Bio's Total Operating Expense for the three months ended in Mar. 2026 was €28.27 Mil. Belite Bio's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €87.12 Mil.

Belite Bio Total Operating Expense Related Terms

Belite Bio Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Belite Bio's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio Total Operating Expense Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 8.67 12.10 29.04 38.20 71.91

Belite Bio Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.35 15.26 19.61 23.98 28.27
STU:D01
20GF Score
Belite Bio Inc STU:D01
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Belite Bio Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €87.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €87.12 Mil mean?
Belite Bio (STU:D01) has a Total Operating Expense of €87.12 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Belite Bio and its competitors.
Is Belite Bio's Total Operating Expense too high?
Belite Bio's current Total Operating Expense is €87.12 Mil. Overall, Belite Bio has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's Total Operating Expense compare to DFTX and LGND?
Belite Bio's Total Operating Expense of €87.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Belite Bio and its competitors. Belite Bio's current Total Operating Expense is €87.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (STU:D01) has a current Total Operating Expense of €87.12 Mil. The current Total Operating Expense is €87.12 Mil. Belite Bio's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Belite Bio (STU:D01), the current Total Operating Expense is €87.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belite Bio Business Description

Other Exchanges BLTE:USA
Address 12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
20GF Score

Get the complete analysis for STU:D01

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€131.00
Price